Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short-term therapy on tumor tissue and serum markers

Clinical Cancer Research

Volumn 13, Issue 1, 2007, Pages 246-252

  Yee, Lisa D ^a,c   Williams, Nita ^a   Wen, Ping ^a   Young, Donn C ^a   Lester, Joanne ^a   Johnson, Maria V ^a   Farrar, William B ^a   Walker, Michael J ^a   Povoski, Stephen P ^a   Suster, Saul ^a   Eng, Charis ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Surgical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INSULIN; KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADULT; AGED; APPETITE DISORDER; ARTICLE; BACKACHE; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD SYMPTOM; DIZZINESS; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HEADACHE; HOT FLUSH; HUMAN; IMMUNOHISTOCHEMISTRY; INCREASED APPETITE; INSULIN RESISTANCE; MIGRAINE; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SINUSITIS; SORE THROAT; TUMOR BIOPSY; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WOUND INFECTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KI-67 ANTIGEN; MIDDLE AGED; PILOT PROJECTS; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 33846334043     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1947     Document Type: Article

References (41)

1. Krey G, Keller H, Mahfoudi A, et al. Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids. J Steroid Biochem Mol Biol 1993;47: 65-73.
2. Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci U S A 1995;92:7921-5.
3. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-4.
4. Chawla A, Lazar MA. Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci U S A 1994;91:1786-90.
5. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ: tissue-specific regulator of an adipocyte enhancer. Genes 1994;8:1224-34.
6. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
7. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR γ. Mol Cell 1998;1:465-70.
8. Yee LD, Sabourin CLK, Li L, et al. Peroxisome proliferator-activated receptor γ activation in human breast cancer. Int J Oncol 1999;15:967-73.
9. Yee LD, Guo Y, Bradbury J, Suster S, Clinton SK, Seewaldt VL. The antiproliferative effects of PPARγ ligands in normal human mammary epithelial cells. Breast Cancer Res Treat 2003;78:179-92.
10. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
11. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
12. Nicol CJ, Yoon M, Ward JM, et al. PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004;25: 1747-55.
13. Zhou X-P, Smith WM, Gimm O, et al. Over-representation of PPAR sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet 2000;37: 410-4.
14. Fleis JL. Statistical methods for rates and proportions. New York: Wiley-Liss and Co; 1981.
15. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
16. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPAR (agonists are mediated via upregulation of PTEN. Curr Biol 2001;11:764-8.
17. Elstner E, Williamson EA, Zang C, et al. Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002;74: 155-65.
18. Gronemeyer H, Gustafsson J-A, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-64.
19. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome- proliferator activated receptor γ (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 2003;106:752-7.
20. Allred CD, Kilgore MW. Selective activation of PPARγ in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 2005;235:21-9.
21. Zhang H, Kuang S-Q, Liao L, Zhou S, Xu J. Haploid inactivation of the Amplified-in-Breast Cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor γ and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Cancer Res 2004;64: 7169-77.
22. Teresi RE, Shaiu C-W, Chen C-S, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone. Int J Cancer 2006;118:2390-8.
23. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 1995;9:794-804.
24. Bonofiglio D, Gabriele S, Aquila S, et al. Estrogen receptor a binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells. Clin Cancer Res 2005;11: 6139-47.
25. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J Biol Chem 2000;275: 18527-33.
26. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
27. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270:26746-9.
28. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143: 998-1007.
29. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-7.
30. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101: 2476-81.
31. Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002;26:747-53.
32. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999;3:799-804.
33. Ikezoe T, Miller CW, Kawano S, et al. Mutational analysis of the peroxisome proliferator-activated receptorg gene in human malignancies. Cancer Res 2001;61:5307-10.
34. Bouancheau D, Buecher B. The PPARγ K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Lett 2005;224:111-6.
35. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-7.
36. Memisoglu A, Hu FB, Hankinson SE, et al. Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary intake in relation to body mass. Hum Mol Genet 2003;12: 2923-9
37. Demetri GD, Fletcher CDM, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999;96:3951-6.
38. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A 2000;97:10990-5.
39. Smith MR, Manola J, Kaufman DS, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a risng serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004;101:1569-74.
40. Kulke MH, Demetri GD, Sharpless NE, et al. A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002;8:395-9.
41. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003;79: 391-7.